Recombinant Cynomolgus PD-L1 (C-Fc)-Target Proteins-EnkiLife-Recombinant Proteins,Antibodies,Kits,Cell Biology

Name	Recombinant Cynomolgus PD-L1 (C-Fc)
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/µg as determined by LAL test.
Construction	Recombinant Cynomolgus CD274 Molecule is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession #	G7PSE7
Host	Human Cells
Species	Cynomolgus
Predicted Molecular Mass	52.4 KDa
Buffer	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Form	Lyophilized
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Alternative Names

B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

Background

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

Note

For Research Use Only , Not for Diagnostic Use.